Description

(Rac)-Efavirenz-d4 is a labelled racemic Efavirenz. Efavirenz (DMP 266) is a potent inhibitor of the wild-type HIV-1 reverse transcriptase with a Ki of 2.93 nM and exhibits an IC95 of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture[1]. (Rac)-Efavirenz-d4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.–Applications-COVID-19-anti-virus-Formula-C14H5D4ClF3NO2-Citation–References-[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Young SD, et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1995 Dec;39(12):2602-5.|[3]Held DM, et al. Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication. J Biol Chem. 2006 Sep 1;281(35):25712-22.|[4]Grobler JA, et al. HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J Biol Chem. 2007 Mar 16;282(11):8005-10.-CASNumber-1246812-58-7-MolecularWeight-319.70-Compound Purity–SMILES-C(#CC1C(C1([2H])[2H])([2H])[2H])C2(C(F)(F)F)C=3C(NC(=O)O2)=CC=C(Cl)C3-Research_Area-Infection; Cancer-Solubility-10 mM in DMSO-Target-Autophagy;HIV;Isotope-Labeled Compounds;Reverse Transcriptase-Isoform–Pathway-Anti-infection;Autophagy;Others-MCE Product type-Isotope-Labeled Compounds